A new point mutation (P157S) in the reverse transcriptase of human immunodeficiency virus type 1 confers low-level resistance to (-)-beta-2',3'-dideoxy-3'-thiacytidine

Antimicrob Agents Chemother. 1999 Aug;43(8):2077-80. doi: 10.1128/AAC.43.8.2077.

Abstract

A P157S mutation in the reverse transcriptase (RT) of human immunodeficiency virus type 1 conferred fivefold resistance to (-)-beta-2',3'-dideoxy-3'-thiacytidine in cell culture. Interestingly, the P157S mutation resulted in increased sensitivity (two- to threefold) to 3'-azido-3'-deoxythymidine (AZT) and to (R)-9-(2-phosphonylmethoxypropyl)adenine (PMPA). A similar increase in susceptibility to AZT and to PMPA was also conferred by the M184V mutation in RT.

Publication types

  • Comparative Study
  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, Non-P.H.S.
  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Anti-HIV Agents / pharmacology*
  • Drug Resistance, Microbial / genetics
  • HIV Reverse Transcriptase / antagonists & inhibitors
  • HIV Reverse Transcriptase / genetics*
  • HIV Reverse Transcriptase / isolation & purification
  • HIV-1 / genetics
  • HIV-1 / pathogenicity
  • HeLa Cells
  • Humans
  • Lamivudine / pharmacology*
  • Point Mutation*
  • Proline / genetics
  • Reverse Transcriptase Inhibitors / pharmacology*
  • Serine / genetics

Substances

  • Anti-HIV Agents
  • Reverse Transcriptase Inhibitors
  • Lamivudine
  • Serine
  • Proline
  • HIV Reverse Transcriptase